Combining the Multi-Targeted Tyrosine Kinase Inhibitor Vandetanib with the Anti-Estrogen Fulvestrant Enhances its Anti-tumor Effect in Non-Small Cell Lung Cancer

Lignende værker

• The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
  af: Zhou, Yan, et al.
  Udgivet: (2015)
• Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells
  af: Hershberger, Pamela A., et al.
  Udgivet: (2009)
• HGF-independent Potentiation of EGFR Action by c-Met
  af: Dulak, Austin M., et al.
  Udgivet: (2011)
• Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents
  af: Wang, Jinfeng, et al.
  Udgivet: (2017)
• Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
  af: Åman Pierre, et al.
  Udgivet: (2008-01-01)